• Home
• About us
• Contact

• News
• People
• Products
• Deals
• Organisations

• Twitter
• Newsletter

Advertisement

Product › Details

cancer drug

	Next higher product group	pharmaceutical
	Status	1998-01-01 sales existent

Record changed: 2021-09-20

Advertisement

More documents for cancer drug

• [1] Oxford BioTherapeutics Ltd.. (9/20/21). "Press Release: Boehringer Ingelheim and Oxford BioTherapeutics Partnership Advances Second Oncology Drug Candidate into the Clinic". Oxford et al.....
• [2] Diaccurate S.A.. (9/8/21). "Press Release: Diaccurate Acquires Clinical Stage Sole-in-Class Targeted Cancer Therapy from Merck KGaA, Darmstadt, Germany". Paris....
• [3] ADC Therapeutics S.A.. (8/26/21). "Press Release: ADC Therapeutics Enters Into a Financing Agreement with HealthCare Royalty for Up to $325 Million". Lausanne....
• [4] MorphoSys AG. (8/26/21). "Press Release: MorphoSys and Incyte Announce the European Commission Approval of Minjuvi (tafasitamab) in Combination with Lenalidomide for the Treatment of Adults with Relapsed or Refractory Diffuse Large B-Cell Lymphoma". Plan...
• [5] MorphoSys AG. (8/24/21). "Press Release: Health Canada Grants Marketing Authorization for Minjuvi (tafasitamab) in Combination with Lenalidomide for the Treatment of Adults with Relapsed or Refractory Diffuse Large B-Cell Lymphoma". Planegg....
• [6] Merck KGaA. (8/23/21). "Press Release: Merck Statement on Phase II Study of Bintrafusp Alfa in First-Line Treatment of Biliary Tract Cancer". Darmstadt....
• [7] Zelluna Immunotherapy AS. (8/19/21). "Press Release: Exclusive License Agreement with the U.S. National Cancer Institute to Develop and Commercialize KK-LC-1 Targeting Allogeneic »Off-the-Shelf« TCR Based Natural Killer (TCR-NK) Cell Therapies". Oslo....
• [8] Immunitas Therapeutics Inc.. (8/18/21). "Press Release: Immunitas Therapeutics Completes $58 Million Series B Financing". Waltham, MA....
• [9] MorphoSys AG. (8/17/21). "Press Release: MorphoSys' Partner Incyte Announced Development and Commercialization Agreement with InnoCare for Tafasitamab in Greater China". Planegg....
• [10] CureVac N.V.. (8/16/21). "Press Release: CureVac Announces Financial Results for the Second Quarter and First Half of 2021 and Provides Business Update". Tübingen, Boston, MA & London....

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Advertisement

» top

» Imprint  |  » Data Privacy  |  » Contact  |  The use of this website requires to accept the » Disclaimer!   |  A project of [iito] Business Intelligence © 2002-2021. Made in Germany.